Record On October 12, Singapore's Health Sciences Authority announced an HSA–Agency for Care Effectiveness Priority Track. It lets selected health products undergo regulatory evaluation and health-technology assessment at the same time, rather than in sequence. HSA also announced a Regulatory Innovation Corridor with the UK MHRA for AI-enabled drug development and trials, and a single entry point for clinical-research engagement.
Why it matters
In most systems, approval and coverage are separate gates run by separate agencies on separate clocks:
- FDA and CMS in the United States;
- MHRA and NICE in the United Kingdom.
A product can be approved and still wait months for a reimbursement decision. Running both reviews together could shorten that gap. It could also force earlier agreement on what evidence counts.
What is not yet known
Which products qualify (HSA says only "selected innovative health products"), whether actual timelines match HSA's projection that the track could shorten the time to a first HTA decision from about one year to six to nine months after regulatory approval (HSA, 12 October 2026), and whether concurrent review changes outcomes or only sequencing. Treat this as an announced design, not a demonstrated result.
Comparison for U.S. readers
The nearest U.S. analogues are the FDA–CMS Parallel Review program for devices, which few products have used, and CMS's 2024 Transitional Coverage for Emerging Technologies (TCET) pathway. Neither guarantees coverage at approval, which is a caution against assuming announced pathways will be used.